search
Back to results

A Trial of tPCS on Parkinson's Disease OFF State

Primary Purpose

Parkinson Disease

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Active tPCS
Sham tPCS
Levodopa tablet
Sponsored by
Western University, Canada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring Parkinson disease OFF state, Noninvasive stimulation

Eligibility Criteria

40 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients diagnosed with Idiopathic Parkinson's disease (IPD).

Exclusion Criteria:

  • Parkinson plus syndromes.
  • Drug-induced parkinsonism.
  • Patients who cannot walk independently or wheelchair-bound.
  • Patients who are not able to provide informed consent.

Sites / Locations

  • London Health Sciences Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Sham Comparator

Active Comparator

Arm Label

Real tPCS

Sham tPCS

Levodopa

Arm Description

Patients will be randomized to any of the 3 arms. In Real tPCS arm, we will give active tPCS for 20 mins.

Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.

Patients will be randomized to any of the 3 arms. In Levodopa arm, we will give 3 tablets of Levodopa-Carbidopa (100/25).

Outcomes

Primary Outcome Measures

Change in Unified Parkinson's disease rating scale (UPDRS) part III
The effectiveness of tPCS in OFF state of PD will be evaluated. Unified Parkinson's disease rating scale (UPDRS) part III will be applied - pre and post stimulation. UPDRS Part III is motor examination that consists of speech, facial expression, rigidity, rest tremor, postural/action tremor, rapid alternating movements for testing bradykinesia, arising from chair, posture, gait, body bradykinesia, postural stability. In each subset, minimum score is 0 and maximum is 4. By adding, total UPDRS part III score is minimum 0 to maximum 108. Higher score means more severity of parkinsonism.
Changes in spatiotemporal gait measures using objective gait analysis
Zeno Walkway Gait carpet will be used and the spatiotemporal details of the gait will be analyzed by ProtoKinetics Movement Analysis Software (PKMAS) software, pre and post stimulation.
Change in upper limb motor kinetics
KinArm will be used pre and post stimulation to have objective measurement of upper limb motor function. Reaching task will be performed using standardized KinArm protocol. Visuomotor function of upper limb will be analyzed by postural control of arm with respect to x and y co-ordinates, angular velocity, acceleration, force and torque.
Changes in Network fragmentation using Quantitative Electroencephalography (EEG)
Network fragmentation will be analyzed by 5 mins of resting quantitative Electroencephalography (EEG), pre and post stimulation. All frequency bands will be analyzed.

Secondary Outcome Measures

Full Information

First Posted
August 9, 2019
Last Updated
August 12, 2019
Sponsor
Western University, Canada
search

1. Study Identification

Unique Protocol Identification Number
NCT04054960
Brief Title
A Trial of tPCS on Parkinson's Disease OFF State
Official Title
A Trial of tPCS on Parkinson's Disease OFF State
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Unknown status
Study Start Date
September 2019 (Anticipated)
Primary Completion Date
September 2021 (Anticipated)
Study Completion Date
October 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Western University, Canada

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A significant number of patients with Parkinson's disease (PD) face motor fluctuations even after repeated titration of the dosing of Levodopa. Dealing with OFF state really becomes problematic for them. Aggravation of bradykinesia, rigidity, tremor and gait difficulty are the common problems in OFF state. Studies are going on drugs like Apomorphine as rescue therapy in OFF state. Recently there are studies with Noninvasive brain stimulation, as an evolving therapeutic option in different neurodegenerative diseases. In this study, the investigators are to evaluate the efficacy of transcranial pulsed current stimulation (tPCS) in the OFF state in PD patients. The investigators will give stimulation via tPCS (active/sham). EEG, Kinematic measurement of upper limb movement via KinArm, Unified Parkinson's Disease Rating Scale (UPDRS) scoring will be done and gait will be assessed via Gait Carpet - pre and post-stimulation. The investigators will evaluate the effectiveness of tPCS as a single modality or in combination with Levodopa in managing OFF state of PD.
Detailed Description
This will be a randomized sham-controlled trial. The investigators have planned to study the efficacy of Transcranial pulsed current stimulation (tPCS) in patients of Parkinson's disease (PD) in their OFF state. Each patient will come in 3 separate days in OFF state. They will first receive either active tPCS or sham tPCS or 3 tabs of Levodopa (100/25) in OFF state. Pre and post intervention analysis will be done. In those, who are receiving tPCS (active/sham), the investigators will give them Levodopa (100/25) after post stimulation assessment done. The patients will be assessed clinically by UPDRS III. EEG (for electrophysiological analysis), Gait Carpet (for Gait analysis) will also be done - before and after a single session of 20 min stimulation via tPCS. The investigators will also compare the effect of tPCS in OFF state, with that of Levodopa in OFF state. The assessment will be done by- Unified Parkinson's disease rating scale III (UPDRS III) Gait via Gait Carpet Quantitative Electroencephalography (qEEG) KinARM Transcranial pulsed current stimulation (tPCS) will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes. For this experiment, 20 minutes of stimulation will be performed. The stimulation would be done to the motor cortex (M1) or supplementary motor area (SMA), based on quantitative electroencephalography (qEEG) findings. For the sham stimulation, the electrode placement will be same, but the electric current will be ramped down 5 seconds. Zeno Walkway is a pressure sensitive electronic roll-up walkway that measures the temporal and spatial parameters of gait which could in turn help in identifying any abnormalities in the gait. The patient walks on the Zeno Walkway mat before and after the tPCS stimulation to find the difference in the gait motion. The Zeno walkway will be used in conjunction with the ProtoKinetics Movement Analysis Software (PKMAS). These data will be captured and collated via the PKMAS software, resulting in numerous spatial, temporal and pressure-related gait parameters. Timed-up-and-go (TUG) (1-5minutes per trial) will be performed. The test consists of rising from chair, walking across the 20-foot gait carpet, turning around off the carpet, walking back and sitting down. This will be performed over 3 trials. Gait analysis provides various additional parameters as output such as stride length, line of progression, step length, toe-offs and other temporal and spatial parameters for analysis. Quantitative EEG signals will be recorded, eyes-closed, no-task, using g.Nautilus g.tec wireless system. The g.tech system uses earclip reference sensors. The patient will be in a quiet place with less light or electromagnetic perturbations. During the resting state recordings, patients are seated in a comfortable arm chair and will be instructed to keep relaxed, with their eyes closed for 5 min. Kinarm will be used to measure the kinematics of upper limb movements, via Reaching tasks. This is basically mechanical handle driven by multiple actuators. A software named BKIN will be used to setup this hardware. The Kinarm initially provides the patients with multiple points to reach in the screen and the patients would try to reach these points using the kinarm handle. The motion of the patients when trying to reach for these points is analysed by kinarm and the data would be provided to us based on this analysis. An paired t test will be used to compare baseline data and post tPCS data. Descriptive analysis of the neurological examination findings will be provided. The output from the KinARM, gait carpet, EEG will be used for further analysis to build a descriptive machine learning model.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
Keywords
Parkinson disease OFF state, Noninvasive stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Real tPCS
Arm Type
Experimental
Arm Description
Patients will be randomized to any of the 3 arms. In Real tPCS arm, we will give active tPCS for 20 mins.
Arm Title
Sham tPCS
Arm Type
Sham Comparator
Arm Description
Patients will be randomized to any of the 3 arms. In Sham tPCS arm, we will give sham tPCS for 20 mins.
Arm Title
Levodopa
Arm Type
Active Comparator
Arm Description
Patients will be randomized to any of the 3 arms. In Levodopa arm, we will give 3 tablets of Levodopa-Carbidopa (100/25).
Intervention Type
Device
Intervention Name(s)
Active tPCS
Intervention Description
Active anodal tPCS will be given for 20 mins to motor cortex (M1) or supplementary motor area (SMA), based on our quantitative EEG findings.
Intervention Type
Device
Intervention Name(s)
Sham tPCS
Intervention Description
For the sham condition, the electrode placement will be the same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation.
Intervention Type
Drug
Intervention Name(s)
Levodopa tablet
Intervention Description
We will give 3 tablets of Levodopa-Carbidopa (100/25).
Primary Outcome Measure Information:
Title
Change in Unified Parkinson's disease rating scale (UPDRS) part III
Description
The effectiveness of tPCS in OFF state of PD will be evaluated. Unified Parkinson's disease rating scale (UPDRS) part III will be applied - pre and post stimulation. UPDRS Part III is motor examination that consists of speech, facial expression, rigidity, rest tremor, postural/action tremor, rapid alternating movements for testing bradykinesia, arising from chair, posture, gait, body bradykinesia, postural stability. In each subset, minimum score is 0 and maximum is 4. By adding, total UPDRS part III score is minimum 0 to maximum 108. Higher score means more severity of parkinsonism.
Time Frame
3 months
Title
Changes in spatiotemporal gait measures using objective gait analysis
Description
Zeno Walkway Gait carpet will be used and the spatiotemporal details of the gait will be analyzed by ProtoKinetics Movement Analysis Software (PKMAS) software, pre and post stimulation.
Time Frame
3 months
Title
Change in upper limb motor kinetics
Description
KinArm will be used pre and post stimulation to have objective measurement of upper limb motor function. Reaching task will be performed using standardized KinArm protocol. Visuomotor function of upper limb will be analyzed by postural control of arm with respect to x and y co-ordinates, angular velocity, acceleration, force and torque.
Time Frame
3 months
Title
Changes in Network fragmentation using Quantitative Electroencephalography (EEG)
Description
Network fragmentation will be analyzed by 5 mins of resting quantitative Electroencephalography (EEG), pre and post stimulation. All frequency bands will be analyzed.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients diagnosed with Idiopathic Parkinson's disease (IPD). Exclusion Criteria: Parkinson plus syndromes. Drug-induced parkinsonism. Patients who cannot walk independently or wheelchair-bound. Patients who are not able to provide informed consent.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mandar Jog, MD
Phone
519-685-8500
Ext
33814
Email
Mandar.Jog@lhsc.on.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mandar Jog, MD
Organizational Affiliation
London Health Sciences Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
London Health Sciences Centre
City
London
State/Province
Ontario
ZIP/Postal Code
N6A 5A5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22581566
Citation
Alon G, Yungher DA, Shulman LM, Rogers MW. Safety and immediate effect of noninvasive transcranial pulsed current stimulation on gait and balance in Parkinson disease. Neurorehabil Neural Repair. 2012 Nov-Dec;26(9):1089-95. doi: 10.1177/1545968312448233. Epub 2012 May 10.
Results Reference
background

Learn more about this trial

A Trial of tPCS on Parkinson's Disease OFF State

We'll reach out to this number within 24 hrs